MaxCyte, Inc.
MaxCyte, Inc. (MXCT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MXCT · as of Jun 8, 2026
Key Statistics
Explore MaxCyte, Inc. Data
mxct stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 66.7%
The MXCT analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $6.00, representing +419.48% upside from the current price of $1.16.
Competitors & Peers
mxct competitorsMXCT
ARMP
AVR
CATX
LNSR
NNOXStock Performance
Full HistoryAbout MaxCyte, Inc.
MaxCyte, Inc. a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation…
what is maxcyte, inc. · mxct stock overview · maxcyte, inc. company profile · who is maxcyte, inc. ceo · mxct NASDAQ · maxcyte, inc. headquarters · maxcyte, inc. business segments
About Stock Overview & Key Data
MaxCyte, Inc. (MXCT) is a Healthcare company in the Medical - Devices industry, listed on NASDAQ since Jul 30, 2021. As of the latest trading session, MXCT stock price is $1.16, with a market capitalization of $127.5M. The stock has returned -45.41% over the past 12 months and -23.23% year-to-date.
According to 6 Wall Street analysts, the consensus rating for MaxCyte, Inc. stock is Buy, with an average 12-month price target of $6.00. In fiscal year 2025, MaxCyte, Inc. reported revenue of $33.0M and net income of -$44.6M. For detailed data — including MaxCyte, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, MaxCyte, Inc. (MXCT) stock price is $1.16. The stock is traded on NASDAQ under the ticker symbol MXCT. The 52-week range is $0.64 – $2.40.